Resultats globals: 2 registres trobats en 0.01 segons.
Articles, 2 registres trobats
Articles 2 registres trobats  
1.
9 p, 1.3 MB Association of baseline absolute neutrophil counts and survival in patients with metastatic colorectal cancer treated with second-line antiangiogenic therapies : exploratory analyses of the RAISE trial and validation in an electronic medical record data set / Grothey, Axel (Mayo Clinic) ; Yoshino, Takayuki (National Cancer Center Hospital East) ; Bodoky, Gyorgy (St László Hospital (Hongria)) ; Ciuleanu, Tudor (The Oncology Institute Prof Dr Ion Chiricută and Iuliu Hațieganu University of Medicine and Pharmacy) ; García-Carbonero, Rocío (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ; García-Alfonso, Pilar (Hospital General Universitario Gregorio Marañón) ; Van Cutsem, Eric (University Hospitals Leuven (Bèlgica)) ; Muro, Kei (Aichi Cancer Center Hospital) ; Mytelka, Daniel S (Formerly of Eli Lilly and Company) ; Li, Li (Eli Lilly and Company) ; Lipkovich, Olga (Eli Lilly and Company) ; Hsu, Yanzhi (Eli Lilly and Company) ; Sashegyi, Andreas (Eli Lilly and Company) ; Ferry, David (Eli Lilly and Company) ; Nasroulah, Federico (Eli Lilly Argentina) ; Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ; Universitat Autònoma de Barcelona
In the RAISE trial, ramucirumab+leucovorin/fluorouracil/irinotecan (FOLFIRI) improved the median overall survival (mOS) of patients with previously treated metastatic colorectal cancer versus patients treated with placebo+FOLFIRI but had a higher incidence of neutropaenia, leading to more chemotherapy dose modifications and discontinuations. [...]
2018 - 10.1136/esmoopen-2018-000347
ESMO open, Vol. 3 (april 2018)  
2.
7 p, 814.0 KB Quality of life during first-line FOLFOX4±panitumumab in RAS wild-type metastatic colorectal carcinoma : results from a randomised controlled trial / Siena, Salvatore (Università degli Studi di Milano (Italy)) ; Tabernero, Josep (Vall d'Hebron Institut d'Oncologia) ; Bodoky, Gyorgy (St László Hospital (Hongria)) ; Cunningham, David (Royal Marsden National Health Service Foundation Trust (United Kingdom)) ; Rivera, Fernando (Hospital Universitario Marqués de Valdecilla (Santander, Cantabria)) ; Ruff, Paul (University of the Witwatersrand (South Africa)) ; Canon, Jean Luc (Grand Hôpital de Charleroi. Service d'Oncologie-Hématologie (Belgium)) ; Koukakis, Reija (Amgen Ltd. Department of Biostatistics (United Kingdom)) ; Demonty, Gaston (Amgen GmbH. Medical Development (Suïssa)) ; Hechmati, Guy (Amgen GmbH. Global Health Economics (Suïssa)) ; Douillard, Jean-Yves (Institut de Cancérologie de l'Ouest (France)) ; Universitat Autònoma de Barcelona
Metastatic colorectal cancer is rarely curable. Improving quality of life is therefore a key treatment goal. We report quality of life for patients with RAS wild-type metastatic colorectal cancer in the PRIME study. [...]
2016 - 10.1136/esmoopen-2016-000041
ESMO open, Vol. 1, Issue 2 (March 2016) , art. e000041  

Vegeu també: autors amb noms similars
2 Bodoky, G
2 Bodoky, G.
Us interessa rebre alertes sobre nous resultats d'aquesta cerca?
Definiu una alerta personal via correu electrònic o subscribiu-vos al canal RSS.